Merck KGaA to build new life science hub in Massachusetts

Merck KGaA

Germany’s Merck KGaA has announced new plans to create a “major hub” for its North American life science business as it prepares to build a new campus in Burlington, MA, but will be leaving its former Billerica base.

The 280,000-square-foot facility (with an option to add an extra 70,000 square feet in the future) will cost around $115 million and should be up and ready by mid-2017. The facility will include a “customer collaboration” lab and training center, according to the company’s statement.

The new center will however see all 850 Billerica-based employees of MilliporeSigma, the U.S. unit of Merck, move into the facility--replacing its Billerica campus with what will be bigger and more “state-of-the-art” digs.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

MilliporeSigma added however that it will maintain its other North American life science hub in St. Louis, Missouri.

“This new and more expansive MilliporeSigma campus gives us a unique, multiuse life science hub in the United States--one that provides our employees and customers with a sustainable and collaborative working environment,” said Udit Batra, CEO of MilliporeSigma, in the statement.

This campus will house what the company calls an “M Lab Collaboration Center,” which is essentially a shared space for its scientists and engineers work together with their life science customers.

The M Lab Collaboration Center will be one of 9 centers worldwide created specifically for collaboration, which includes training and customer experiments. Other locations will include Brazil, China, France, India, Singapore and South Korea, the biotech said.

“For nearly a decade, Merck KGaA has built a significant presence in Massachusetts and we are extremely pleased to support their expansion in Burlington through the MassWorks Infrastructure Program,” added Gov. Charlie Baker in the statement.

“Building long-lasting public-private partnerships is vital to growing our economy, and the MilliporeSigma campus represents significant investment and confidence in our shared future as a global life science center.”

Merck has a number of businesses and units which focus on manufacturing, biosimilars, consumer health and life science R&D. The company has recently been ramping up its R&D focus, with a near $900 million deal struck with Pfizer ($PFE) a few years back to further development of its checkpoint inhibitor candidate. 

- check out the release

Related Articles:
Merck KGaA, Pfizer help RNA modification biotech to £12M Series A
Pfizer, Merck KGaA partner PD-L1 drug with Verastem's failed cancer drug

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.